產品詳情
簡單介紹：
Anti-PDE8B抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PDE8B抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-PDE8B
Cat. Number:
Anti-PDE8B抗體KL-12588R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The protein encoded by this gene is a cyclic nucleotide phosphodiesterase (PDE) that catalyzes the hydrolysis of the second messenger cAMP. The encoded protein, which does not hydrolyze cGMP, is resistant to several PDE inhibitors. Defects in this gene are a cause of autosomal dominant striatal degeneration (ADSD). Several Anti-PDE8B抗體transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jul 2010]
Also known as:
3' 5' cyclic nucleotide phosphodiesterase 8B; 3'5' cyclic nucleotide phosphodiesterase 8B; Cell proliferation-inducing gene 22 protein; FLJ11212; High affinity cAMP specific and IBMX insensitive 3' 5' cyclic phosphodiesterase 8B; Anti-PDE8B抗體High affinity cAMP specific and IBMX insensitive 3'5' cyclic phosphodiesterase 8B; High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B; High-affinity cAMP-specific and IBMX-insensitive 3'5'-cyclic phosphodiesterase 8B; HSPDE 8B; HsPDE8B; PDE 8B; PDE8B; PDE8B_HUMAN; Phosphodiesterase 8B; Phosphodiesterase8B; PIG22.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugated synthetic Anti-PDE8B抗體peptide derived from human PDE8B.
●
Predicted Molecular Weight: 99kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-PDE8B抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-PDE8B抗體
Optimal working dilutions must be determined by the end user.
